Branded Generics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others), By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region & Competition, 2020-2030F

Market Overview

Global Branded Generics Market was valued at USD 261.41 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.20% through 2030. Branded generics are medicines or pharmaceutical drugs that have been re-released on the market under a different brand name. These are re-released at a lesser cost, and the shape, size, colour, and flavour may differ, even though the medication remains the same. This is due to the fact that the medicine's or pharmaceutical drug's patent has expired. Drugs that can be used to treat hypertension, diabetes, back pain, thyroid, and arthritis, among other conditions, are re-released at cheaper costs in order to stay in the market and survive competition. However, it is important to highlight that, despite the alterations made in the re-release of the drug, the quality remains the same. The functions that the medicine would accomplish are not compromised in any way.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a major driving force behind the expansion of the Global Branded Generics Market. Approximately 9 million people succumb to cancer annually, while 4 million deaths are attributed to chronic respiratory diseases like asthma and COPD, and another 2 million result from diabetes-related complications. However, the global distribution of disease burden and access to advanced healthcare solutions remains highly uneven, with disparities particularly evident in low- and middle-income regions where medical infrastructure, early diagnostics, and treatment accessibility are significantly limited. With a growing global disease burden, healthcare systems and consumers are increasingly turning to cost-effective and reliable treatment options, making branded generics a preferred choice.  Chronic diseases such as cardiovascular diseases (CVDs), diabetes, cancer, respiratory disorders, and arthritis are becoming more prevalent due to factors such as aging populations, unhealthy lifestyles, and environmental changes. According to the World Health Organization (WHO), non-communicable diseases (NCDs) account for nearly 74% of all global deaths, highlighting the urgent need for long-term treatment solutions. Increased demand for continuous medication supply for long-term disease management. Greater emphasis on cost-effective treatment alternatives, making branded generics a viable solution. Higher healthcare spending by governments and private insurers to address chronic disease care.

Unlike acute conditions that require short-term medication, chronic diseases often necessitate lifelong treatment regimens. This sustained demand for drugs translates into consistent sales growth for branded generics, as they offer a balance between affordability and reliability. Steady and predictable market demand, ensuring long-term revenue streams for pharmaceutical companies. Greater preference for branded generics over expensive innovator drugs for chronic disease management. Higher prescription adherence due to cost savings, leading to increased market penetration. With aging populations in key markets such as Europe, North America, and parts of Asia, the incidence of chronic diseases is rising. By 2050, 80% of the global elderly population will reside in low- and middle-income countries, creating significant economic and healthcare challenges for these regions. The rate of population aging is accelerating at an unprecedented pace, outstripping historical trends. Notably, in 2020, individuals aged 60 and above surpassed the number of children under five, signaling a demographic shift. Between 2015 and 2050, the share of people over 60 is set to nearly double from 12% to 22%, reshaping workforce dynamics, healthcare demand, and social support systems worldwide. Older individuals are more susceptible to conditions like hypertension, osteoporosis, diabetes, and neurodegenerative disorders, further driving demand for cost-effective medications. Increased geriatric healthcare expenditure benefiting branded generics manufacturers. Greater need for polypharmacy (multiple medications), boosting sales across various therapeutic categories. Rising pharmaceutical investments in age-related disease treatments, strengthening the branded generics market.

Growing Acceptance by Physician and Patient

Physicians' willingness to prescribe branded generics can directly impact their market growth. If physicians are confident in the quality and effectiveness of branded generics, they are more likely to prescribe them to their patients. Physician endorsement and confidence in the efficacy of branded generics can dispel concerns that patients might have about switching from a branded medication to a generic version. When physicians trust and recommend these alternatives, patients are more likely to accept and use them. Physicians often take into account the financial burden on their patients when prescribing medications. If physicians believe that branded generics offer similar therapeutic benefits as their branded counterparts, they may be more inclined to prescribe them to help patients save on healthcare costs. Pharmaceutical companies and healthcare institutions can play a role in educating physicians about the quality, safety, and equivalency of branded generics compared to branded drugs. Proper education can positively influence physicians' acceptance and prescribing habits. Patients may be concerned about switching from a well-known branded medication to a generic version. Positive experiences and successful treatment outcomes with branded generics can build patients' confidence in their effectiveness, leading to increased acceptance. Patients often trust their physicians' recommendations. If physicians explain the advantages of branded generics, including their affordability and equivalent therapeutic effects, patients are more likely to accept them. The cost factor is a significant driver of patient acceptance. Patients who cannot afford expensive branded medications may be more open to using branded generics as long as they are assured of their safety and efficacy.

Growing Demand for Affordable Medications

The rising demand for affordable medications is a critical driver fueling the expansion of the Global Branded Generics Market. Nearly 30% of Americans report non-adherence to prescribed medications due to prohibitive drug costs, highlighting a critical affordability gap in the U.S. healthcare system. Projections indicate that over the next decade, more than 1.1 million Medicare beneficiaries could face preventable fatalities solely due to the financial inaccessibility of essential treatments, underscoring the urgent need for cost-control measures and policy interventions in the pharmaceutical sector. As healthcare costs continue to escalate worldwide, governments, insurers, healthcare providers, and patients are actively seeking cost-effective alternatives without compromising on quality. Branded generics have emerged as a preferred solution, offering a balance between affordability and reliability. Below is a comprehensive analysis of how this growing demand is shaping the global market. Healthcare expenditure is rising globally due to inflation, higher R&D costs, and increasing chronic disease prevalence. Patients, healthcare systems, and insurers are under pressure to manage these costs, making branded generics a viable and cost-efficient alternative to expensive innovator drugs. Lower-cost alternatives to high-priced brand-name drugs are gaining traction. Governments and insurers are encouraging the adoption of branded generics to contain healthcare costs. Patients can access essential medications at reduced prices, improving treatment adherence.

Governments worldwide are implementing policies to promote generic drug usage as part of their healthcare cost-control measures. Subsidies and incentives for pharmaceutical companies producing branded generics. Price control measures on branded drugs, pushing demand for affordable alternatives. Expansion of public healthcare programs that prioritize branded generics in national formularies. Increased government procurement of branded generics for public hospitals and clinics. Greater regulatory support for fast-track approvals, enabling quicker market entry. Strengthened insurance reimbursements for branded generics, making them more accessible. Countries expanding their universal healthcare systems and insurance programs are increasingly favoring branded generics over expensive innovator drugs. Insurance providers prefer covering branded generics due to their cost-effectiveness and comparable efficacy. Higher reimbursement rates for branded generics, increasing patient preference. Improved market penetration as healthcare coverage expands, especially in emerging economies. Greater adoption of generic substitution policies, ensuring more prescriptions favor branded generics.

Download Free Sample Report

Key Market Challenges

Regulatory Hurdles

Generic medications, including branded generics, need to go through regulatory approval processes to ensure their safety, quality, and efficacy. Delays or complexities in the approval process can slow down the introduction of new branded generic products to the market. Regulatory authorities often have strict requirements for demonstrating the bioequivalence of branded generics to their branded counterparts. Meeting these requirements can be challenging and time-consuming, potentially causing delays in market entry. Regulatory challenges can arise when dealing with the patents of the original branded drugs. Patent disputes and legal battles can delay or prevent the launch of branded generics even after the patent has expired. Different countries have varying regulatory frameworks and requirements for generic medications. Navigating these diverse regulations can be complex for pharmaceutical companies looking to market branded generics globally. Ensuring consistent quality and adherence to manufacturing standards is crucial for the acceptance of generic medications. Regulatory hurdles related to quality control can affect the perception and trust of healthcare professionals and patients in branded generics. Some regulatory systems offer periods of data exclusivity or market exclusivity for innovator drugs, which can delay the entry of generic alternatives. This can hinder the availability of branded generics, especially in markets with longer exclusivity periods.

Changing Healthcare Policies

Governments often implement pricing regulations to control healthcare costs and ensure affordability for patients. While these regulations can lead to lower prices for medications, they can also impact the profitability of generic manufacturers, including those producing branded generics. If pricing regulations result in extremely low profit margins, manufacturers might be discouraged from producing or promoting branded generics. Reimbursement policies determine how much of the cost of a medication is covered by insurance or government healthcare programs. Changes in reimbursement policies, such as reduced reimbursement rates for branded generics, can influence patient access and demand for these products. Healthcare policies can influence the inclusion or exclusion of specific medications on formularies, which are lists of drugs covered by insurance plans or healthcare systems. If branded generics are excluded from formularies due to policy changes, it can limit their market reach and growth potential. Some healthcare policies and guidelines encourage the use of generic medications over branded drugs to reduce costs. While this can benefit the healthcare system and patients, it might impact the market potential for branded generics, which are positioned as a bridge between branded and generic drugs. Changes in intellectual property laws or policies related to market exclusivity can affect the competitive landscape for branded generics. If policies extend market exclusivity periods for branded drugs, it can delay the entry of generic alternatives, including branded generics. Changing policies related to parallel imports (importing and selling branded generics from lower-cost markets) can impact the availability and pricing of branded generics in certain regions. Healthcare policies that lack clarity or transparency can lead to confusion among patients and healthcare professionals. This confusion might affect patient and physician acceptance of branded generics, hindering their market growth.

Key Market Trends

Advancements in Digital Health Integration

Digital health technologies can improve patient engagement by providing tools for medication reminders, tracking, and adherence. Branded generics, as more affordable alternatives, can benefit from increased patient engagement, leading to improved treatment outcomes and patient loyalty. Branded generics are often used for chronic disease management. Digital health solutions enable remote monitoring of patients' health conditions, which is particularly useful for managing chronic diseases. This integration can enhance patient compliance with medication regimens, contributing to the growth of the market. Digital health platforms can facilitate telemedicine consultations, where physicians can remotely diagnose and prescribe medications, including branded generics. This can increase the accessibility of these medications to patients, especially in regions with limited healthcare infrastructure. Digital health solutions can enable personalized treatment plans based on patient data and health metrics. Branded generics can be tailored to fit individual patient needs, resulting in better treatment outcomes and patient satisfaction. Digital health integration can improve awareness of branded generics among patients and healthcare providers. Through digital platforms, manufacturers can educate users about the benefits, availability, and cost savings associated with branded generics. Pharmaceutical companies can use data analytics to gain insights into market trends, patient preferences, and healthcare utilization patterns. This information can guide marketing strategies and product positioning for branded generics.

Development Biosimilars in the Branded Generics Landscape

Biosimilars compete with both the original biologic drugs and branded generics in some cases. This competition can drive down prices, making treatment more affordable for patients. The presence of biosimilars can put pressure on the pricing of branded generics, leading to increased adoption due to cost savings. Biosimilars can expand the market by providing more affordable options for patients who might have otherwise been unable to afford biologic treatments. This expanded patient base can also benefit branded generics by increasing awareness and demand for affordable alternatives. Biosimilars can capture a portion of the market share of both original biologics and branded generics. Depending on the competitive landscape, this redistribution can impact the growth of the branded generics market. The introduction of biosimilars can lead to increased awareness and education efforts around biologics and their alternatives. This increased education can benefit branded generics by creating a more informed market that understands the value of cost-effective options. The regulatory pathways developed for biosimilars can also impact regulations around generic medications, including branded generics. Changes in regulatory standards or guidelines for biosimilars might indirectly influence regulations for branded generics. As patients become more familiar with biosimilars and their benefits, they might become more open to considering alternative treatment options, including branded generics. Patient preferences and acceptance can be influenced by the broader context of biosimilar adoption.

Segmental Insights

Drug Class Insights

Based on the Drug Class, the Anti–Hypertensive segment is anticipated to witness substantial market growth throughout the forecast period. This growth can be attributed to multiple factors, such as Hypertension is a global health concern, affecting millions of people worldwide. As the prevalence of hypertension continues to rise due to factors like sedentary lifestyles and unhealthy diets, there is a growing need for accessible and cost-effective treatment options. Branded generics provide a solution by offering affordable alternatives to branded anti-hypertensive drugs. Hypertension is a chronic condition that often requires lifelong medication. Branded generics cater to the need for continuous treatment by providing affordable options for patients who may require long-term therapy. Governments and healthcare systems are under pressure to control healthcare costs. Branded generics can help healthcare systems manage their budgets more efficiently by providing cost-effective options for hypertension treatment. Many anti-hypertensive drugs have already lost their patent protection or are on the verge of patent expiry. This opens the door for generic manufacturers, including those producing branded generics, to enter the market and offer more affordable options.

Distribution Channel Insights

Based on the Distribution channel segment, the Online Pharmacy segment emerges as the fastest growing segment in the Global Branded Generics Market. The growing penetration of the internet, coupled with the widespread use of smartphones, has significantly influenced the shift toward online purchasing of pharmaceuticals. Consumers increasingly prefer the convenience of ordering medications from the comfort of their homes, avoiding long wait times and in-person visits to traditional pharmacies. Online pharmacies often offer branded generics at lower prices compared to brick-and-mortar stores due to reduced overhead costs. Bulk purchasing, direct-to-consumer models, and strategic partnerships with manufacturers allow online platforms to pass on cost benefits to customers, enhancing their competitive edge.

The integration of e-commerce platforms with healthcare services, including telemedicine, electronic prescriptions, and digital payment options, has streamlined the customer experience. Many online pharmacies have leveraged AI-powered prescription verification and automated order fulfillment, making the procurement of branded generics seamless.

Download Free Sample Report

Regional Insights

Based on region, North America region emerges as the largest market in the Global Branded Generic Market in 2024, primarily due to North America has seen a significant number of patent expirations for blockbuster drugs, creating opportunities for generic manufacturers to introduce branded generic versions. As a result, the region has experienced substantial growth in the branded generics market as companies capitalize on these opportunities. The high healthcare costs in North America have driven the demand for more affordable alternatives to branded drugs. Branded generics provide a cost-effective option for patients and healthcare systems, contributing to their growth in the region. Branded generics address the need for accessible medications, particularly for chronic diseases that are prevalent in North America. They help patients manage their conditions without the financial burden of expensive branded medications. The presence of health insurance systems in North America, including private insurance and government programs like Medicare and Medicaid, can encourage the use of more affordable branded generics by providing coverage for these medications.

Recent Developments

• In June 2024, Teva Pharmaceuticals, Inc., the U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announced the market launch of its authorized generic version of Victoza® (liraglutide injection 1.8mg) in the United States. This launch marks a significant expansion of Teva’s injectable diabetes treatment portfolio, providing patients with a cost-effective alternative to the branded medication.
• In November 2023, Teva Pharmaceuticals Inc., the U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announced the regulatory approval of its generic version of Forteo® in the United States. The company anticipates the product will be commercially available across the U.S. market in the coming weeks, expanding patient access to an affordable alternative for osteoporosis treatment.
• In March 2023, United Nations-backed Medicines Patent Pool (MPP) has granted Viatris, Inc., Aurobindo Pharma, and Cipla Inc. sublicenses to make low-cost branded generic versions of Apretude, a HIV drug manufactured by GSK plc. ViiV, a company established by a joint venture of GSK plc. and Pfizer Inc., will help the companies with the development, production, and supply of the branded generic versions.
• In May 2021, Teva Pharmaceutical Industries Ltd. announced the release of the first generic version of THIOLA® (tiopronin) tablets in the United States. These tablets are intended to be used in conjunction with high fluid intake, alkali, and diet modification to prevent the formation of cystine (kidney) stones in adults and pediatric patients with severe homozygous cystinuria who are older than nine years old and who are not responsive to these treatments alone.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals Inc.
• Sanofi-Aventis.
• Sun Pharmaceutical Industries Inc.
• Dr Reddy's Laboratories Inc.
• Endo International PLC.
• GlaxoSmithKline LLC.
• Pfizer Inc.
• Viatris Inc.
• Apotex Inc.

Report Scope:

In this report, the Global Branded Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Branded Generics Market, By Drug Class:

o   Alkylating Agents

o   Antimetabolites

o   Hormones

o   Anti – Hypertensive

o   Lipid Lowering Drugs

o   Antidepressant

o   Antipsychotics

o   Antiepileptics

o   Others

• Branded Generics Market, By Application:

o   Oncology

o   Cardiovascular Diseases

o   Neurological Diseases

o   Acute & Chronic Pain

o   Gastrointestinal Diseases

o   Dermatological Diseases

o   Others

• Branded Generics Market, By Distribution Channel:

o   Hospital Pharmacy

o   Retail Pharmacy

o   Online Pharmacy

• Branded Generics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Branded Generics Market.

Available Customizations:

Global Branded Generics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Branded Generics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com